MaxCyte

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MaxCyte reports robust Q4 earnings, poised for strategic growth

MaxCyte delivered impressive financial results in Q4 2022, showcasing strong revenue growth and a solid core business performance.
Despite facing challenges such as regulatory risks and industry dynamics, the company's strategic strengths and opportunities position it for continued success.
By maintaining a focus on innovation, partnership expansion, and financial prudence, MaxCyte aims to drive growth and navigate industry complexities effectively.

MaxCyte reports revenue decline but eyes growth through strategic partnerships

MaxCyte faced revenue declines in Q1 2023 due to industry challenges but remains positive about its future prospects and partnerships.
Despite financial setbacks, the company is focused on growth opportunities through new partnerships and potential product approvals.
Strategic guidance aims for revenue growth in 2023 and a healthy year-end cash position, signaling stability and long-term planning.

MaxCyte reports Q2 revenue decline but anticipates product approvals

MaxCyte faces revenue challenges but maintains confidence in its outlook with a strong partnership pipeline. The company's financials show a healthy gross margin and a focus on R&D for future growth. Anticipation surrounds the first commercial approval of products enabled by its platform.

MaxCyte meets Q3 revenue targets, eyes FDA milestone payments

MaxCyte's Q3 performance met expectations, with a focus on overcoming challenges in core business areas. The company's strengths lie in its optimism about non-viral engineered cell therapy trends and strong financial position.
While facing challenges in PA sales and operating expenses, MaxCyte sees opportunities in FDA approval milestones, revenue potential from SPL programs, and long-term growth through partnerships and industry support.

MaxCyte reports 2023 revenue decline but strong FDA approval growth

MaxCyte's 2023 performance saw revenue decline but significant achievements with FDA approval for CASGEVY and SPL client growth.
Despite challenges in core revenue, the company's strong financial position and robust SPL portfolio offer growth opportunities.
Guidance for 2024 indicates improved trends with flat to 5% growth, emphasizing the potential in SPL partnerships and financial stability.
Stabilization in funding and patient adoption present opportunities for revenue growth and market expansion in the cell therapy sector.

MaxCyte exceeds Q1 revenue expectations, poised for strategic growth

MaxCyte delivered strong Q1 2024 results, surpassing revenue expectations and demonstrating robust financial performance. With a focus on managing expenses and driving growth, the company is well-positioned to capitalize on its competitive strengths and market opportunities. Challenges lie in sustaining revenue growth and balancing expenses with expansion.

MaxCyte reports robust Q2 revenue, eyes cell therapy growth

MaxCyte's Q2 2024 performance showed solid revenue growth and a strong gross margin. The company's focus on cell therapy innovation and strategic partnerships positions it well for future growth.

MaxCyte exceeds revenue expectations, poised for sustainable growth

MaxCyte's Q3 2024 performance reflects robust revenue growth and strategic investments for long-term success.
While facing challenges like margin impact and cost management, the company's strengths in partnerships and leadership drive opportunities for expansion.
With increased revenue guidance and a disciplined spend approach, MaxCyte is poised for sustained growth and profitability.
Overall, MaxCyte's focus on core revenue, strategic partnerships, and leadership development sets a strong foundation for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences:

MaxCyte to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the third quarter of 2022 after the U.S. market close on Wednesday, November 9th, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

MaxCyte Inc (AIM:MXCT) said it signed a strategic platform license (SPL) for its Flow Electroporation technology and ExPERT platform with Vertex Pharmaceuticals (NASDAQ:VRTX), a biotechnology company. The AIM-listed company will receive platform licensing fees and program-related revenue from the gene editing therapy through the agreement, it said.

MaxCyte signs strategic platform license with biotech

Vertex Pharmaceuticals will continue to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

MaxCyte Inc confirmed it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland's I-270 Biotech Corridor. The company's new 67,000-square-foot facility significantly increases its in-house manufacturing capacity, as well as research and process development lab space.

MaxCyte confirms it has relocated its headquarters to within Maryland's I-270 Biotech Corridor

MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?

Expanded facilities illustrate MaxCyte's commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities.

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 4:40 p.m. Eastern Time.

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

MaxCyte Inc (AIM:MXCT) has again raised its full-year outlook as it continued to enjoy strong growth in the cell therapy market. Revenue came in at US$9.6mln for the second quarter of 2022, up 35% year-on-year, with the core business growing 45% and drug discovery up 4%.

MaxCyte lifts guidance again as cell therapy demand continues to grow

MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Sean Menarguez - Director of Investor Relations Doug Doerfler - Founder, President & Chief Executive Officer Ron Holtz - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Operator Good day, and thank you for standing by, and welcome to MaxCyte Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q2 2022 Results - Earnings Call Transcript

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the second quarter of 2022 after the U.S. market close on Wednesday, August 10th, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

MaxCyte Inc (AIM:MXCT) said it has signed a strategic platform license for South Korean chemical company LG Chem to get non-exclusive clinical and commercial rights to use its Flow Electroporation technology and ExPERT platform. The AIM-listed cell-engineering company is entitled to receive platform licensing fees and program-related revenue.

MaxCyte licenses Flow Electroporation and ExPERT technology to LG Chem

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on May 10, 2022, the Compensation Committee of MaxCyte's Board of Directors granted stock options to purchase an aggregate of 73,700 shares of MaxCyte's common stock to six (6) newly hired employees. The stock options were granted as material inducements to employment with MaxCyte in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the MaxCyte, Inc. 2021 Inducement Plan (the “2021 Inducement Plan”).

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Inc (AIM:MXCT) has raised guidance after a strong start to the year that saw the cell engineering specialist's revenues increase by 78% in the first quarter. It expects the top-line growth of at least 25% from the core business, while milestone income from licensing agreements is set to be in the order of US$4mln.

MaxCyte raises financial guidance after strong start to the year

MaxCyte, Inc. (NASDAQ:MXCT ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Doug Doerfler – President and Chief Executive Officer Amanda Murphy – Chief Financial Officer Sean Menarguez – Investor Relations Conference Call Participants Stephanie Iannetta – Cowen and Company Matthew Larew – William Blair Mark Belford – Stephens Inc. Vidyun Bais – BTIG Operator Good day and thanks for standing by. Operator Good day and thank you for standing by.

MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q1 2022 Results - Earnings Call Transcript

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million

MaxCyte Reports First Quarter Financial Results

GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the first quarter of 2022 after the U.S. market close on Monday, May 9th, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

MaxCyte Inc (AIM:MXCT) said Amanda Murphy has stepped down as Chief Financial Officer with Ron Holtz, currently Chief Accounting Officer, taking over as interim replacement while it looks for a permanent successor. MaxCyte also announced first quarter of 2022 would rise by at least 70% to US$11mln from US$6.5mln a year ago.

Maxcyte sales surge, CFO stands down

GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that Amanda Murphy has resigned from her position as Chief Financial Officer, effective as of April 15, 2022, to pursue other interests. Ron Holtz, current Senior Vice President and Chief Accounting Officer, has been named Interim Chief Financial Officer effective upon Ms. Murphy's departure.

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

MaxCyte, Inc. (MXCT) CEO Doug Doerfler on Q4 2021 Results - Earnings Call Transcript

MaxCyte Provides Initial 2022 Guidance MaxCyte Provides Initial 2022 Guidance

MaxCyte Reports Fourth Quarter and Full Year Financial Results

Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership.

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22nd, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

MaxCyte Inc (AIM:MXCT) has seen its shares grow after a US deal. The company, which specialises in technology for ex-vivo cell engineering, has signed a licence agreement with Intima Bioscience, which is developing genetically engineered cell therapies for solid tumor cancer.

News for MaxCyte Stock (MXCT)